Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses
Authors:
Open Access
- 15 December 2025
- journal article
- research article
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 406
Abstract
SAMHD1 is a human deoxyribonucleoside triphosphatase (dNTPase) known for its role as a restriction factor that targets a wide spectrum of viruses, its involvement in autoimmune disease Aicardi–Goutières syndrome (AGS), and its participation in innate immune regulation. The role of SAMHD1 in cancer, particularly its contribution to drug resistance, has gained increasing attention in recent years. One significant scientific challenge is how to inhibit SAMHD1 function in tumor cells while preserving its function in normal primary cells. Herein, we identified that increased SAMHD1 expression levels correlate with poor prognosis across multiple cancer types, and that SAMHD1 is upregulated in a variety of tumors. Through proteomic analysis and drug screening, we identified a promising strategy for selectively depleting tumor-associated SAMHD1 while minimizing its impact on SAMHD1 expression in key normal cell types. Our approach effectively enhanced tumor cytotoxicity when combined with multiple chemotherapeutic agents and suppressed tumor growth in vivo. Moreover, selective depletion of tumor-associated SAMHD1 activated innate immune responses, leading to enhanced tumor cell killing by immune cells. Collectively, these findings suggest that targeting tumor-specific SAMHD1 represents a novel and promising therapeutic strategy for cancers characterized by elevated SAMHD1 expression, offering potential for improved treatment outcomes in cancer patients with high SAMHD1 expression.Keywords
Funding Information
- National Natural Science Foundation of China (82341055)
- National Natural Science Foundation of China (81701988)
This publication has 74 references indexed in Scilit:
- Pimitespib: First ApprovalDrugs, 2022
- Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trialAnnals of Oncology, 2022
- S-adenosylmethionine-dependent methyltransferase inhibitor DZNep blocks transcription and translation of SARS-CoV-2 genome with a low tendency to select for drug-resistant viral variantsAntiviral Research, 2021
- Defective modulation of LINE-1 retrotransposition by cancer-associated SAMHD1 mutantsBiochemical and Biophysical Research Communications, 2019
- First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profileInvestigational New Drugs, 2017
- SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous RecombinationCell Reports, 2017
- Hsp90-Tau Complex Reveals Molecular Basis for Specificity in Chaperone ActionCell, 2014
- Modulation of LINE-1 and Alu/SVA Retrotransposition by Aicardi-Goutières Syndrome-Related SAMHD1Cell Reports, 2013
- Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemiaAnnals of Hematology, 2004
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984